Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
7.900
-0.020 (-0.25%)
Streaming Delayed Price
Updated: 1:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Via
InvestorPlace
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.
February 19, 2024
The lofty target is closer to being within reach than it may seem at first.
Via
The Motley Fool
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
February 18, 2024
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...
Via
Talk Markets
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
Why Is MindMed (MNMD) Stock Up 8% Today?
February 12, 2024
MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.
Via
InvestorPlace
Exposures
Product Safety
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?
February 02, 2024
Via
Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
January 30, 2024
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.
Via
Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.
Via
Benzinga
New Study Reveals Suggestibility's Role In Antidepressant Effects Of Psilocybin Therapy
January 25, 2024
Study found that suggestibility did not predict response to psilocybin therapy for MDD patients, challenging concerns about placebo effects.
Via
Benzinga
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
January 13, 2024
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.
Via
Talk Markets
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
January 09, 2024
Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024.
Via
InvestorPlace
3 Big New Catalysts for Psychedelics Stocks in 2024
January 08, 2024
This could be the year that psychedelics stocks start to fly.
Via
The Motley Fool
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub
Via
Benzinga
Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research
January 05, 2024
Biotechnology company Compass Pathways plc (NASDAQ: CMPS) and Greenbrook TMS Inc (NASDAQ: GBNH) have entered into a three-year research collaboration agreement to explore delivery models
Via
Benzinga
AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect
January 03, 2024
The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for...
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
Via
Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...
Via
Benzinga
Psychedelic Drug Stocks Index Up In December; Down YTD
December 27, 2023
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.
Via
Talk Markets
Do Psychedelic Treatments Always Require Psychotherapy? Well, We Need To Look 'Beyond Reductionism'
December 19, 2023
The question of whether psychedelic treatments always require psychotherapy is one hotly debated among researchers, and answers -as well as backstories- vary throughout the whole spectrum.
Via
Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
December 18, 2023
Biden To Decide On Psychedelic Therapy Bill
Via
Benzinga
Psychedelic Drug Stocks Index Declined 1.6% This Week
December 17, 2023
Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.
Via
Talk Markets
Topics
ETFs
Compass Pathways: A Higher-Risk But Potentially Higher-Reward Company In The Biotech Arena
December 16, 2023
If you can afford it – and if it would not be too big a position in your portfolio – putting $2,000 into a couple of speculative biotechs might be a good idea here. One I like is Compass Pathways.
Via
Talk Markets
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
December 11, 2023
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy
Via
Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week
December 10, 2023
The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.
Via
Talk Markets
Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective, AMA Study Finds
December 06, 2023
A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provi
Via
Benzinga
Investing in Mental Health: 3 Stocks in the Wellness Space
December 05, 2023
Mental health stocks can be a great addition to your portfolio as its importance becomes increasingly recognized.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.